Updated July 2026. No nicotine vaccine has been approved. Historical setbacks include NicVAX (Nabi Biopharmaceuticals) — Phase 3 failed 2011 due to insufficient antibody titers in most vaccinees; NIC7-001 (Selecta Biosciences) — Phase 1/2 discontinued due to low titers. Contemporary work focuses on more immunogenic hapten-carrier chemistry and mRNA-encoded anti-nicotine approaches (preclinical). Meanwhile, pharmacotherapies remain the standard: varenicline (Chantix — Pfizer discontinued August 2021 due to nitrosamine contamination, generic returned to market 2024), bupropion, and nicotine replacement therapies. Behavioral treatments and vape-cessation programs dominate the current smoking-cessation landscape in the absence of a viable vaccine.
Comprehensive tracking of nicotine vaccine development for smoking cessation - active immunization blocking nicotine from reaching brain reward centers. Smoking kills 480,000 Americans annually (1,300/day), 8 million globally. 28 million current US smokers despite known health risks. Nicotine vaccines induce antibodies binding nicotine in bloodstream, preventing BBB crossing, eliminating euphoria/reinforcement. Multiple Phase 2/3 trials: NicVAX (Nabi), NicQb (Cytos), SEL-068 (Selecta). Conjugate vaccines (nicotine hapten + carrier protein + adjuvant). Challenges: individual variability in antibody response, high nicotine loads from heavy smoking overwhelming antibodies. Novel approaches: nanoparticle vaccines, slow-release formulations, combination with NRT (patches, gum) and behavioral therapy. Complementary to cessation aids (varenicline, bupropion).
Smoking kills 480,000 Americans annually (1,300 deaths/day), 8 million globally. Leading preventable cause of death in US and worldwide. 16 million Americans living with smoking-caused disease: lung cancer (130,000 deaths/year), COPD (120,000 deaths/year), heart disease (140,000), stroke (35,000). Secondhand smoke kills 41,000 annually. $300 billion annual US costs ($225B medical, $75B lost productivity). Despite 70% of smokers wanting to quit, only 7% succeed annually with current methods. Nicotine highly addictive - 80-90% who try cigarettes become daily smokers. Vaccines offer novel pharmacological approach: blocking nicotine's rewarding effects at source, making relapse less reinforcing, improving long-term abstinence rates beyond current 10-20% with behavioral therapy + medications.
📊 View all nicotine vaccine trials on ClinicalTrials.gov →
🌍 CDC Smoking & Tobacco Use →
🌍 American Lung Association - Quit Smoking →
🌍 Smokefree.gov →
📰 Latest Nicotine Vaccine News (Google) →